Retour

Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation

News Clinical Study

Ability to dose TERN-701 without regard to food represents a key potential differentiator within the allosteric BCR-ABL inhibitor class

GlobeNewswire Inc. • 29/04/2024 à 22:05:00
Terns Pharmaceuticals, Inc. Common Stock
Address: 1065 EAST HILLSDALE BLVD., SUITE 100
Postal Code: 94404
City: FOSTER CITY
State: CA
Phone Number: 650-525-5535 EXT.101
Website: https://www.ternspharma.com
Status: Active
Company Info

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.

List Date2021-02-05
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001831363
Composite figiBBG00KK1SJ08
Share Class figiBBG00KK1SJ17
Market Cap359,591,777 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees66
Share Class Shares Outstanding64680000
Weighted Shares Outstanding64674780
Round Lot100
Updated date2024-05-12
Stats
Last 5 days
15-05
14-05
13-05
10-05
9-05
Last
5.96
6.02
5.895
5.555
5.73
Variance
-0.53%
2.17%
6.08%
-3.12%
3.97%
Open
5.992
5.892
5.557
5.734
5.511
Highest
6.23
6.112
6.17
5.955
5.968
Lowest
6.204
6.07
6.16
5.955
5.949
History
PeriodVarhighestlowest
1 week
10.13%
5.968
5.949
1 month
30.04%
5.043
4.75
3 month
-17.2%
8.3
4.75
6 month
57.64%
3.85
3.59
1 year
-50.42%
12.63
3.26
3 year
-60.95%
17.285
1.45
5 year
-64.19%
19.12
1.45
10 year
-64.19%
19.12
1.45
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-15 2023-08-08 2023-11-14 UNPUB
Assets 301,285,000 289,697,000 271,687,000 UNPUB
Current Assets 299,664,000 288,315,000 270,455,000 UNPUB
Current Liabilities 12,109,000 14,238,000 12,087,000 UNPUB
Equity 287,683,000 274,150,000 258,425,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 287,683,000 274,150,000 258,425,000 UNPUB
Liabilities 13,602,000 15,547,000 13,262,000 UNPUB
Liabilities And Equity 301,285,000 289,697,000 271,687,000 UNPUB
Noncurrent Assets 1,621,000 1,382,000 1,232,000 UNPUB
Noncurrent Liabilities 1,493,000 1,309,000 1,175,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-15 2023-08-08 2023-11-14 UNPUB
Exchange Gains/Losses -10,000 -94,000 -34,000 UNPUB
Net Cash Flow 41,119,000 -103,435,000 -43,026,000 UNPUB
Net Cash Flow, Continuing 41,129,000 -103,341,000 -42,992,000 UNPUB
Net Cash Flow From Financing Activities 27,580,000 489,000 20,000 UNPUB
Net Cash Flow From Financing Activities, Continuing 27,580,000 489,000 20,000 UNPUB
Net Cash Flow From Investing Activities 27,931,000 -90,837,000 -22,313,000 UNPUB
Net Cash Flow From Investing Activities, Continuing 27,931,000 -90,837,000 -22,313,000 UNPUB
Net Cash Flow From Operating Activities -14,382,000 -12,993,000 -20,699,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -14,382,000 -12,993,000 -20,699,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-15 2023-08-08 2023-11-14 UNPUB
Comprehensive Income/Loss -21,122,000 -18,255,000 -29,828,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -21,122,000 -18,255,000 -29,828,000 UNPUB
Other Comprehensive Income/Loss 406,000 -359,000 -61,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-15 2023-08-08 2023-11-14 UNPUB
Basic Earnings Per Share 0 0 0 UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 24,157,000 21,159,000 33,184,000 UNPUB
Diluted Earnings Per Share 0 0 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -21,528,000 -17,896,000 -29,767,000 UNPUB
Income/Loss From Continuing Operations Before Tax -21,468,000 -17,824,000 -29,709,000 UNPUB
Income Tax Expense/Benefit 60,000 72,000 58,000 UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -21,528,000 -17,896,000 -29,767,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -21,528,000 -17,896,000 -29,767,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -21,528,000 -17,896,000 -29,767,000 UNPUB
Operating Expenses UNPUB UNPUB UNPUB UNPUB
Operating Income/Loss -24,157,000 -21,159,000 -33,184,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 0 0 0 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-16 2022-08-08 2022-11-09 2023-03-27
Assets 156,669,000 144,860,000 192,586,000 287,026,000
Current Assets 154,111,000 142,601,000 190,537,000 285,185,000
Current Liabilities 6,165,000 6,044,000 7,481,000 8,468,000
Equity 148,716,000 137,216,000 183,694,000 276,943,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 148,716,000 137,216,000 183,694,000 276,943,000
Liabilities 7,953,000 7,644,000 8,892,000 10,083,000
Liabilities And Equity 156,669,000 144,860,000 192,586,000 287,026,000
Noncurrent Assets 2,558,000 2,259,000 2,049,000 1,841,000
Noncurrent Liabilities 0 0 1,411,000 1,615,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-16 2022-08-08 2022-11-09 2023-03-27
Exchange Gains/Losses -8,000 -61,000 -154,000 -178,000
Net Cash Flow 8,000 -30,901,000 46,171,000 95,536,000
Net Cash Flow, Continuing 16,000 -30,840,000 46,325,000 95,714,000
Net Cash Flow From Financing Activities 3,820,000 -3,696,000 61,001,000 167,095,000
Net Cash Flow From Financing Activities, Continuing 3,812,000 -3,688,000 61,001,000 167,095,000
Net Cash Flow From Investing Activities 9,488,000 -15,974,000 -1,240,000 -22,272,000
Net Cash Flow From Investing Activities, Continuing 9,488,000 -15,974,000 -1,240,000 -22,272,000
Net Cash Flow From Operating Activities -13,300,000 -11,162,000 -13,436,000 -49,109,000
Net Cash Flow From Operating Activities, Continuing -13,300,000 -11,162,000 -13,436,000 -49,109,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-16 2022-08-08 2022-11-09 2023-03-27
Comprehensive Income/Loss -13,773,000 -13,930,000 -16,927,000 -60,829,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -14,331,000 -14,275,000 -16,927,000 -60,829,000
Other Comprehensive Income/Loss 0 0 -107,000 -484,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-16 2022-08-08 2022-11-09 2023-03-27
Basic Earnings Per Share UNPUB UNPUB 0 -2
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 13,825,000 14,084,000 17,292,000 62,029,000
Diluted Earnings Per Share UNPUB UNPUB 0 -2
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -13,773,000 -13,930,000 -16,820,000 -60,345,000
Income/Loss From Continuing Operations Before Tax -13,752,000 -13,924,000 -16,807,000 -59,987,000
Income Tax Expense/Benefit 21,000 6,000 13,000 358,000
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -13,773,000 -13,930,000 -16,820,000 -60,345,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -13,773,000 -13,930,000 -16,820,000 -60,345,000
Net Income/Loss Available To Common Stockholders, Basic -13,773,000 -13,930,000 -16,820,000 -60,345,000
Operating Expenses UNPUB UNPUB UNPUB UNPUB
Operating Income/Loss -13,825,000 -14,084,000 -17,292,000 -62,029,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-14 2021-08-16 2021-11-15 2022-03-07
Assets 199,241,000 188,007,000 179,890,000 168,070,000
Current Assets 198,042,000 186,872,000 178,794,000 166,930,000
Current Liabilities 8,377,000 5,818,000 6,893,000 6,820,000
Equity 190,002,000 181,332,000 172,156,000 160,303,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 190,002,000 181,332,000 172,156,000 160,303,000
Liabilities 9,239,000 6,675,000 7,734,000 7,767,000
Liabilities And Equity 199,241,000 188,007,000 179,890,000 168,070,000
Noncurrent Assets 1,199,000 1,135,000 1,096,000 1,140,000
Noncurrent Liabilities 0 0 841,000 947,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-14 2021-08-16 2021-11-15 2022-03-07
Exchange Gains/Losses -62,000 11,000 4,000 -25,000
Net Cash Flow 23,975,000 -31,240,000 -2,838,000 -27,155,000
Net Cash Flow, Continuing 24,037,000 -31,251,000 -2,842,000 -27,130,000
Net Cash Flow From Financing Activities 135,169,000 -1,589,000 797,000 134,393,000
Net Cash Flow From Financing Activities, Continuing 135,169,000 -1,589,000 797,000 134,393,000
Net Cash Flow From Investing Activities -96,816,000 -20,902,000 4,443,000 -119,696,000
Net Cash Flow From Investing Activities, Continuing -96,816,000 -20,902,000 4,443,000 -119,696,000
Net Cash Flow From Operating Activities -14,316,000 -8,760,000 -8,082,000 -41,827,000
Net Cash Flow From Operating Activities, Continuing -14,316,000 -8,760,000 -8,082,000 -41,827,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-14 2021-08-16 2021-11-15 2022-03-07
Comprehensive Income/Loss -13,337,000 -10,738,000 -11,828,000 -50,372,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -13,445,000 -10,680,000 -11,828,000 -50,372,000
Other Comprehensive Income/Loss 0 0 7,000 -214,000
Other Comprehensive Income/Loss Attributable To Parent -13,445,000 -10,680,000 -11,828,000 -50,372,000
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-14 2021-08-16 2021-11-15 2022-03-07
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB 50,650,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 13,296,000 10,818,000 11,868,000 50,860,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -13,337,000 -10,738,000 -11,835,000 -50,158,000
Income/Loss From Continuing Operations Before Tax -13,298,000 -10,724,000 -11,815,000 -49,650,000
Income Tax Expense/Benefit 39,000 14,000 20,000 508,000
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -13,337,000 -10,738,000 -11,835,000 -50,158,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -13,337,000 -10,738,000 -11,835,000 -50,158,000
Net Income/Loss Available To Common Stockholders, Basic -13,337,000 -10,738,000 -11,835,000 -50,158,000
Operating Expenses UNPUB UNPUB UNPUB 50,860,000
Operating Income/Loss -13,296,000 -10,818,000 -11,868,000 -49,860,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 1,000,000
Calendar
16 May 2024 (Time UTC) Actual Previous Consensus
★★
10:00
United States
★
09:15
United States
APR
0.500
0.100
★★
09:15
United States
APR
0.000
★
09:15
United States
APR
78.400
78.400
★
09:15
United States
APR
★
08:30
United States
MAY 10
215000.000
★★
08:30
United States
MAY 10
231000.000
220000.000
★★
08:30
United States
APR
0.400
0.400
★
08:30
United States
APR
0.400
★
08:30
United States
APR
1321000.000
1410000.000
★★
08:30
United States
APR
-14.700
★
08:30
United States
APR
-1.400
★
08:30
United States
MAY 10
1785000.000
1780000.000
★★
08:30
United States
MAY
-10.700
★
08:30
United States
MAY
20.000
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:TERN240419P00015000 OPASPS Put American 100 15 BATO 2024-04-19
O:TERN240419C00015000 OCASPS Call American 100 15 BATO 2024-04-19
O:TERN240419P00012500 OPASPS Put American 100 12.5 BATO 2024-04-19
O:TERN240419P00010000 OPASPS Put American 100 10 BATO 2024-04-19
O:TERN240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:TERN240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:TERN240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:TERN240419C00012500 OCASPS Call American 100 12.5 BATO 2024-04-19
O:TERN240419C00010000 OCASPS Call American 100 10 BATO 2024-04-19
O:TERN240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:TERN240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:TERN240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:TERN240315P00010000 OPASPS Put American 100 10 BATO 2024-03-15
O:TERN240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:TERN240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:TERN240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:TERN240315C00010000 OCASPS Call American 100 10 BATO 2024-03-15
O:TERN240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:TERN240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:TERN240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:TERN240216P00012500 OPASPS Put American 100 12.5 BATO 2024-02-16
O:TERN240216P00010000 OPASPS Put American 100 10 BATO 2024-02-16
O:TERN240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:TERN240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:TERN240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:TERN240216C00012500 OCASPS Call American 100 12.5 BATO 2024-02-16
O:TERN240216C00010000 OCASPS Call American 100 10 BATO 2024-02-16
O:TERN240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:TERN240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:TERN240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:TERN240119P00025000 OPASPS Put American 100 25 BATO 2024-01-19
O:TERN240119P00022500 OPASPS Put American 100 22.5 BATO 2024-01-19
O:TERN240119P00020000 OPASPS Put American 100 20 BATO 2024-01-19
O:TERN240119P00017500 OPASPS Put American 100 17.5 BATO 2024-01-19
O:TERN240119P00015000 OPASPS Put American 100 15 BATO 2024-01-19
O:TERN240119P00012500 OPASPS Put American 100 12.5 BATO 2024-01-19
O:TERN240119P00010000 OPASPS Put American 100 10 BATO 2024-01-19
O:TERN240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:TERN240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:TERN240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:TERN240119C00025000 OCASPS Call American 100 25 BATO 2024-01-19
O:TERN240119C00022500 OCASPS Call American 100 22.5 BATO 2024-01-19
O:TERN240119C00020000 OCASPS Call American 100 20 BATO 2024-01-19
O:TERN240119C00017500 OCASPS Call American 100 17.5 BATO 2024-01-19
O:TERN240119C00015000 OCASPS Call American 100 15 BATO 2024-01-19
O:TERN240119C00012500 OCASPS Call American 100 12.5 BATO 2024-01-19
O:TERN240119C00010000 OCASPS Call American 100 10 BATO 2024-01-19
O:TERN240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:TERN240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:TERN240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:TERN231215P00010000 OPASPS Put American 100 10 BATO 2023-12-15
O:TERN231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:TERN231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:TERN231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:TERN231215C00010000 OCASPS Call American 100 10 BATO 2023-12-15
O:TERN231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:TERN231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:TERN231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:TERN231117P00010000 OPASPS Put American 100 10 BATO 2023-11-17
O:TERN231117P00007500 OPASPS Put American 100 7.5 BATO 2023-11-17
O:TERN231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:TERN231117P00002500 OPASPS Put American 100 2.5 BATO 2023-11-17
O:TERN231117C00010000 OCASPS Call American 100 10 BATO 2023-11-17
O:TERN231117C00007500 OCASPS Call American 100 7.5 BATO 2023-11-17
O:TERN231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:TERN231117C00002500 OCASPS Call American 100 2.5 BATO 2023-11-17
O:TERN231020P00025000 OPASPS Put American 100 25 BATO 2023-10-20
O:TERN231020P00022500 OPASPS Put American 100 22.5 BATO 2023-10-20
O:TERN231020P00020000 OPASPS Put American 100 20 BATO 2023-10-20
O:TERN231020P00017500 OPASPS Put American 100 17.5 BATO 2023-10-20
O:TERN231020P00015000 OPASPS Put American 100 15 BATO 2023-10-20
O:TERN231020P00012500 OPASPS Put American 100 12.5 BATO 2023-10-20
O:TERN231020P00010000 OPASPS Put American 100 10 BATO 2023-10-20
O:TERN231020P00007500 OPASPS Put American 100 7.5 BATO 2023-10-20
O:TERN231020P00005000 OPASPS Put American 100 5 BATO 2023-10-20
O:TERN231020P00002500 OPASPS Put American 100 2.5 BATO 2023-10-20
O:TERN231020C00025000 OCASPS Call American 100 25 BATO 2023-10-20
O:TERN231020C00022500 OCASPS Call American 100 22.5 BATO 2023-10-20
O:TERN231020C00020000 OCASPS Call American 100 20 BATO 2023-10-20
O:TERN231020C00017500 OCASPS Call American 100 17.5 BATO 2023-10-20
O:TERN231020C00015000 OCASPS Call American 100 15 BATO 2023-10-20
O:TERN231020C00012500 OCASPS Call American 100 12.5 BATO 2023-10-20
O:TERN231020C00010000 OCASPS Call American 100 10 BATO 2023-10-20
O:TERN231020C00007500 OCASPS Call American 100 7.5 BATO 2023-10-20
O:TERN231020C00005000 OCASPS Call American 100 5 BATO 2023-10-20
O:TERN231020C00002500 OCASPS Call American 100 2.5 BATO 2023-10-20
O:TERN230915P00015000 OPASPS Put American 100 15 BATO 2023-09-15
O:TERN230915P00012500 OPASPS Put American 100 12.5 BATO 2023-09-15
O:TERN230915P00010000 OPASPS Put American 100 10 BATO 2023-09-15
O:TERN230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:TERN230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:TERN230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:TERN230915C00015000 OCASPS Call American 100 15 BATO 2023-09-15
O:TERN230915C00012500 OCASPS Call American 100 12.5 BATO 2023-09-15
O:TERN230915C00010000 OCASPS Call American 100 10 BATO 2023-09-15
O:TERN230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:TERN230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:TERN230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:TERN230818P00025000 OPASPS Put American 100 25 BATO 2023-08-18
O:TERN230818P00022500 OPASPS Put American 100 22.5 BATO 2023-08-18
O:TERN230818P00020000 OPASPS Put American 100 20 BATO 2023-08-18
O:TERN230818P00017500 OPASPS Put American 100 17.5 BATO 2023-08-18
O:TERN230818P00015000 OPASPS Put American 100 15 BATO 2023-08-18
O:TERN230818P00012500 OPASPS Put American 100 12.5 BATO 2023-08-18
O:TERN230818P00010000 OPASPS Put American 100 10 BATO 2023-08-18
O:TERN230818P00007500 OPASPS Put American 100 7.5 BATO 2023-08-18
O:TERN230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:TERN230818P00002500 OPASPS Put American 100 2.5 BATO 2023-08-18
O:TERN230818C00025000 OCASPS Call American 100 25 BATO 2023-08-18
O:TERN230818C00022500 OCASPS Call American 100 22.5 BATO 2023-08-18
O:TERN230818C00020000 OCASPS Call American 100 20 BATO 2023-08-18
O:TERN230818C00017500 OCASPS Call American 100 17.5 BATO 2023-08-18
O:TERN230818C00015000 OCASPS Call American 100 15 BATO 2023-08-18
O:TERN230818C00012500 OCASPS Call American 100 12.5 BATO 2023-08-18
O:TERN230818C00010000 OCASPS Call American 100 10 BATO 2023-08-18
O:TERN230818C00007500 OCASPS Call American 100 7.5 BATO 2023-08-18
O:TERN230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:TERN230818C00002500 OCASPS Call American 100 2.5 BATO 2023-08-18
News Stream
Stocks Earnings Releases and Operating Results
Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
Interim data from initial dose escalation cohorts from Phase 1 CARDINAL trial of TERN-701 (allosteric BCR-ABL) in CML expected in 2H24
GlobeNewswire Inc. • 2d ago
Management Management Changes
Terns Pharmaceuticals Announces Leadership Changes
FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Scott Harris as chief development officer (CDO) effective May 28, 2024 and the upcoming departure of Erin Quirk, M.D., president, head of research and development. Dr. Quirk will be transitioning her responsibilities and leaving the company to pursue other opportunities effective June 3, 2024.
GlobeNewswire Inc. • 1w ago
Stocks Changes in company's own shares
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of May 1, 2024 an equity inducement award to Melita Sun Jung, the Company’s new Chief Business Officer, under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). The equity award was approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to Ms. Jung’s acceptance of employment with Terns.
GlobeNewswire Inc. • 1w ago
News Clinical Study
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
Ability to dose TERN-701 without regard to food represents a key potential differentiator within the allosteric BCR-ABL inhibitor class
GlobeNewswire Inc. • 2w ago
Management Directors and Officers
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Melita Sun Jung as chief business officer, effective April 22, 2024.
GlobeNewswire Inc. • 1mo ago
Stocks Earnings Releases and Operating Results
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
Interim data from initial dose escalation cohorts from Phase 1 trial of TERN-701 (allosteric BCR-ABL) for treatment of CML expected in second half of 2024
GlobeNewswire Inc. • 2mo ago
Health Health
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
FOSTER CITY, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for TERN-701 for the treatment of chronic myeloid leukemia (CML). TERN-701, the Company’s internally discovered allosteric BCR-ABL tyrosine kinase inhibitor (TKI), is in Phase 1 clinical development with interim data from initial dose escalation cohorts expected in the second half of 2024.
GlobeNewswire Inc. • 2mo ago
News Advisory
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of March 1, 2024 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). The equity award was approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee’s acceptance of employment with Terns.
GlobeNewswire Inc. • 2mo ago
Calendar Calendar of Events
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
FOSTER CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in March.
GlobeNewswire Inc. • 2mo ago
Stocks Changes in company's own shares
Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted effective as of March 1, 2024 equity inducement awards to Amy Burroughs, the Company’s new Chief Executive Officer, under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). The equity awards were approved by the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employee’s acceptance of employment with Terns.
GlobeNewswire Inc. • 3mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT